Ambrisentan Drug Asset Due Diligence Report 2026

This Ambrisentan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ambrisentan can convert its Small molecule drug profile and ETA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ambrisentan (query alias: ambrisentan)
Modality / target	Small molecule drug; ETA; ETA antagonists
Highest global status	Approved
Originator	Abbott Laboratories
Active developers	Viatris Ltd. (New Zealand), GSK Plc, GlaxoSmithKline Trading Services Ltd.

The MCP disease footprint includes Pulmonary arterial hypertension associated with connective tissue disease, Idiopathic pulmonary arterial hypertension, Pulmonary Arterial Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07245680	Phase 3	Recruiting	186	Mesurement of the risk profile according to the non-invasive 4-risk strata method
ChiCTR2600118415	Phase 2	Pending	30	Anxiety level: the HAM-A scores were measured at baseline and 3 months after the intervention.
ChiCTR2600117083	Not Applicable	Pending	356	Pulmonary Arterial Pressure Change from Baseline

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension

Phase 3; n=203; evaluation: Positive. Reported fields: -; PAH progression = 12.0 %

A Real-world Pharmacovigilance Study on Endothelin Receptor Antagonists for Treatment of Pulmonary Artery Hypertension

Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Adverse Event: death = Macitentan and Bosentan had statistically significant ROR of deaths when compared to Ambrisentan ; Adverse Event: death = Macitentan and Bosentan had statistically significant ROR of deaths when compared to Ambrisentan ; Adverse Event: death = Macitentan and Bosentan had statistically significant ROR of deaths when compared to Ambrisentan

EFFECT OF TREATMENT WITH AMBRISENTAN IN PATIENTS WITH SYSTEMIC SCLEROSIS AND MILD PULMONARY ARTERIAL HYPERTENSION: LONG-TERM FOLLOW-UP DATA FROM EDITA STUDY

Phase 2; n=34; evaluation: Positive. Reported fields: mPAP = 1.91 mmHg (SD, 2.98); mPAP = -1.53 mmHg (SD, 2.53)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ambrisentan addresses Pulmonary arterial hypertension associated with connective tissue disease, Idiopathic pulmonary arterial hypertension, Pulmonary Arterial Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2006-03-07	GlaxoSmithKline And Myogen Announce Pulmonary Arterial Hypertension Partnership; GlaxoSmithKline To Commercialize Ambrisentan In All Territories Outside Of The U.S.	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan”. The milestone feed surfaced a patent-application signal described as “Method for determining particle size and/or particle size distribution of ambrisentan and application thereof”. The milestone feed surfaced a patent-application signal described as “Method for NASH risk assessment in patients having a metabolic disorder”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO